Clinical Trials Logo

Recurrent Ovarian Cancer clinical trials

View clinical trials related to Recurrent Ovarian Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04718740 Completed - Clinical trials for Recurrent Ovarian Cancer

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Start date: June 25, 2021
Phase: Phase 1
Study type: Interventional

Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer. Secondary objective: To evaluate the safety of single dose of fluzoparib, caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion or fluzoparib in combination with caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer.

NCT ID: NCT03430518 Completed - Clinical trials for Recurrent Ovarian Cancer

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Start date: May 17, 2018
Phase: Phase 1
Study type: Interventional

This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.

NCT ID: NCT02849353 Completed - Clinical trials for Recurrent Ovarian Cancer

Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent ovarian cancer.

NCT ID: NCT02788708 Completed - Clinical trials for Primary Peritoneal Carcinoma

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Start date: May 27, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenvatinib mesylate when given together with paclitaxel in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer that has come back or grown. Lenvatinib mesylate may stop the growth of tumor cells by blocking a protein needed for cell growth and may block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenvatinib mesylate and paclitaxel together may work better in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT02737787 Completed - Ovarian Cancer Clinical Trials

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

Start date: April 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.

NCT ID: NCT02303912 Completed - Clinical trials for Recurrent Ovarian Cancer

Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer

ProGem2
Start date: November 2014
Phase: Phase 1
Study type: Interventional

A first in human experimental treatment in which an experimental medicine,Nuc-1031, is used in combination with a standard cancer medicine, carboplatin, to treat ovarian cancer which reappear after standard cancer treatment. The aim of the trial is to determine safety, effectiveness, and clinical activity of this combination treatment.

NCT ID: NCT02195973 Completed - Clinical trials for Recurrent Ovarian Cancer

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer. Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).

NCT ID: NCT02090582 Completed - Palliative Care Clinical Trials

H.O.P.E: Helping Ovarian Cancer Patients Cope

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effect of the gynecologic oncologists with palliative care specialist collaboration (GO-PC) intervention on patient quality of life.

NCT ID: NCT01869400 Completed - Clinical trials for Recurrent Ovarian Cancer

An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

NIS-OvaYond
Start date: April 2013
Phase:
Study type: Observational

Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined patient groups, which are not representative for the whole patient population. Especially elderly patients and patients with co-morbidities are underrepresented in clinical trials. This non-interventional study will examine the efficiency and toxicity of the Yondelis® + PLD combination therapy in a general patient population to evaluate if the data collected in the clinical trials can be assigned to a general patient population.

NCT ID: NCT01809379 Completed - Clinical trials for Recurrent Ovarian Cancer

Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer

Start date: February 2013
Phase: Phase 2
Study type: Interventional

This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure chemotherapy in women with recurrent ovarian cancer